Research

During the last meeting of the Board, it has been decided that the current Rare neurological diseases task force, founded in 2016, will be transformed into the first EAN Coordinating Panel.

In order to give our members a deeper insight into the work of EAN’s Scientific Panels, EANpages will feature a different Scientific Panel each month along with a video interview with its co-chairs, explaining the Scientific Panel’s focus, it’s aims and achievements. For November, you can watch a video interview with Marie Vidailhet, Chair of the EAN Scientific Committee where she introduces the Scientific Panels and their important role.

The two European Reference Networks (ERNs) for Rare Neurological Diseases and Rare Neuromuscular Diseases (ERN-RND and ERN-EuroNMD) are launching a new joint educational program in collaboration with the European Academy of Neurology.

This month’s selected paper addresses the risk of neurological deficits in people with cavernomas treated with antithrombotic medication. Perhaps counter-intuitively, the authors report a lower risk of intracerebral haemorrhage in patients taking antithrombotic medication (mostly antiplatelet therapy). The study therefore provides reassurance for clinicians managing patients with this relatively common, and often incidental, vascular finding that antithrombotic therapy does not appear harmful; conversely, there could be some benefit, but this requires further evaluation in a randomised controlled trial.

Zika virus circulation has decreased but there is a possibility of its emergence or re-emergence in all areas with competent mosquito vectors.

Levetiracetam and NOACs

Online voting for the EAN Scientific Panel Management Group members will begin on 8 October and continue through to 22 October.

The next examination of the European Board of Neurology (EBN) will take place on Friday, 22 May 2020 at the EAN Congress in Paris.

This month’s selected paper is a working group report that addresses a recently described disorder, limbic-predominant age-related TDP-43 encephalopathy (LATE), which is emerging as an important cause of cognitive impairment in the elderly. The group make recommendations for standardised neuropathological evaluation and identify research avenues to better understand this evolving new disease phenotype.

Second dose of intravenous immunoglobulin for Guillain-Barre syndrome

Antiparanodal antibodies in CIDP.

Role of right frontal regions in cognition: evidence from intraoperative stimulation in awake people

Fluoroquinolone Use Linked to Higher Risk of Peripheral Neuropathy

EXTEND study: More evidence on thrombolysis beyond traditional time windows

A consensus review on the development of palliative care for patients with chronic and progressive neurological disease.